U.S. markets close in 46 minutes

Akebia Therapeutics, Inc. (AKBA)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.5000+0.1100 (+4.60%)
As of 3:14PM EDT. Market open.
Sign in to post a message.
  • M
    Mr. Market
    Truly speaking, I loaded more this morning under $2.45. Now, I have 80K shares. Will keep it for 6 months and I will triple my investment. 👍
  • C
    I sense a momentum shift towards Bullish sentiment? anyone else sense it?
  • M
    Short interest has increased by 1 Million ( 12.4%) between 8/31 when the stock price was $10.38 and 9/15, when the stock price was $2.65. Most of the additional shorts were generated after the announcement and immediate price drop to sub $3/per sh. I would expect that with the continued high volume of trading since 9/15, that the short interest has continued to increase as the share price, with no immediate news coming, has continued to grind lower. But the positional shorts as opposed to day traders are reliant upon share owners capitulating to the lower prices. BIG MISTAKE!!!! Whether institutional or retail holders, there is NO LOGIC to be selling at these levels. I do believe that at some time soon, we will see some insider purchases, but that is just my opinion, based on the price and that the news was no where near bad enough to precipitate a 75% drop in the share price.
  • M
    Mr. Market

    AKBA market cap is Just 10% of rival FGEN market cap.

    FGEN HIF drug is approved in China and Japan.
    AKBA HIF drug is approved in Japan.

    FGEN 2019 revenue was $256M.
    AKBA 2019 revenue was $340M.

    I think AKBA will be back to $10 soon.
  • a
    This is good that akebia forcing other big pharma to pay up for it's Auryxia IP infringement.


    On September 24, 2020, Keryx Biopharmaceuticals, Inc. (“Keryx”), a wholly owned subsidiary of Akebia Therapeutics, Inc., and its licensors, Panion & BF Biotech, Inc. (“Panion”) and Chen Hsing Hsu, M.D. entered into a settlement and license agreement with Lupin Atlantis Holdings SA (“Lupin”) and Lupin Ltd. This settlement resolves patent litigation brought by Keryx and Panion in response to Lupin and Lupin Ltd.’s Paragraph IV certification notice letters regarding their Abbreviated New Drug Applications (“ANDAs”) seeking approval to market a generic version of Auryxia® (ferric citrate) tablets prior to the expiration of the applicable patents. Pursuant to the terms of the settlement, and consistent with Keryx’s prior ANDA settlements with Teva Pharmaceuticals USA, Inc. and its wholly owned, indirect subsidiary, Watson Laboratories, Inc., and with Par Pharmaceutical, Inc., Keryx and Panion will grant Lupin and Lupin Ltd. a license to market a generic version of Auryxia in the United States beginning on March 20, 2025 (subject to U.S. Food and Drug Administration approval), or earlier under certain circumstances customary for settlement agreements of this nature. Additionally, in accordance with the agreement, the parties will terminate all ongoing litigation among Keryx, Panion, Lupin, Lupin Ltd. and Dr. Hsu regarding Auryxia patents pending in the United States District Court for the District of Delaware. The settlement and license agreement is confidential and subject to review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
    Security and Exchange Commission SEC Akebia Therapeutics, Inc. Form 8-K
    Security and Exchange Commission SEC Akebia Therapeutics, Inc. Form 8-K
  • B
    Wait... is that... green!?
  • T
    What was previously expected to be a three-way battle in the novel HIF-PHI renal anemia drug class now has one man down. Akebia Therapeutics has posted a surprise trial flop, which one analyst said could hand the rival FibroGen-AstraZeneca team an ea
    What was previously expected to be a three-way battle in the novel HIF-PHI renal anemia drug class now has one man down. Akebia Therapeutics has posted a surprise trial flop, which one analyst said could hand the rival FibroGen-AstraZeneca team an ea
  • B
    Less than a week after its launch on August 26, Mitsubishi Tanabe Pharma’s new hypoxia-inducible factor prolyl hydroxylase (HIF-PH) inhibitor Vafseo (vadadustat) is already facing shortages due to stronger-than-expected demand, forcing the company to curb shipments for one of its…

  • M
    Mr. Market
    AKBA is the stock of 2021
  • M
    Mr. Market
    Vadatustat works perfectly, and has achived primary and secondary endpoints. They just need to fix its side effect, which they are working on now, then AKBA will hit $50.
  • L
    Big mystery is no insider purchases.
  • E
    I find it amazing this stock can instantly lose 75% of its value in seconds, then not deviate from this low level for almost a months
  • D
    If they drive this close to 2 I'm buying big today. Dutch
  • S
    It is interesting to note that FGEN's stock price has not been affected by the recent
    MACE results. In the FGEN Phase III MACE NDD trials they compared ROXA to a control group taking a placebo. As the life expectancy of people with combined anemia and CKD is less than those with CDK only, obtaining positive MACE results comparing an anemia mitigating drug to a placebo is a very low bar to hurdle. AKBA's NDD MACE trial compared VADU to an injectable EPO drug, where both drugs serve to mitigate anemia. This is a much higher bar to hurdle. It is highly probable that VADU would also have successful MACE results in a trial using a placebo control group. Surely the FDA will be aware of difference and, as such, will probably give conditional approval to both companies for both the NDD and DD indications.
  • a
    In Cantor call finished just now, Butler looks very confident about getting the Non-Dialysis approval. He also mentioned that street is not factoring the dialysis approval from FDA which alone is $2B market and VADUSTAT is clearly has big advantage over competitions.

    Hold on tight on these shares. Not a single share should be sold at this time.
  • J
    I am holding 25K share and my target is $7.5
  • A
    We have established a 75 percent probability ratio that Vadadustat is approved for non dialysis patients as part of a warning label only.

    The sell off even including FDA disapproval for non dialysis patients remains unattached to the reality that continues to exist inside the business.
  • s
    Considering latest trial data show the drug has high mortality than placeabo, PPS really should trade around cash value of 1.25/sh. Not counting burn rate in next year....

    Until the mortality is resolved, no real upside to PPS...

    Good Luck to all and do your due diligence always...
  • G
    Any BO by the Japanese partner will be around $12 per share that is their secondary issue price.

    I’ll hold for a $12 price target.